Arch Biopartners (TSXV:ARCH) Dividends per Share : C$0.00 (TTM As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

What is Arch Biopartners Dividends per Share?

Arch Biopartners's dividends per share for the three months ended in Dec. 2023 was C$0.00. Its dividends per share for the trailing twelve months (TTM) ended in Dec. 2023 was C$0.00. Its Dividend Payout Ratio for the three months ended in Dec. 2023 was 0.00. As of today, Arch Biopartners's Dividend Yield % is 0.00%.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of Arch Biopartners was -0.60% per year. The lowest was -0.60% per year. And the median was -0.60% per year.

For more information regarding to dividend, please check our Dividend Page.

Arch Biopartners Dividends per Share Historical Data

The historical data trend for Arch Biopartners's Dividends per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arch Biopartners Dividends per Share Chart

Arch Biopartners Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Dividends per Share

Get a 7-Day Free Trial

Arch Biopartners Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Dividends per Share	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Arch Biopartners's Dividends per Share

For the Biotechnology subindustry, Arch Biopartners's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Arch Biopartners's Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arch Biopartners's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Arch Biopartners's Dividend Yield % falls into.

Arch Biopartners Dividends per Share Calculation

Dividends paid to per common share.

Arch Biopartners (TSXV:ARCH) Dividends per Share Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Arch Biopartners's Dividend Payout Ratio for the quarter that ended in Dec. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Dec. 2023 )	/	EPS without NRI (Q: Dec. 2023 )
	=	0	/	-0.013
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

Arch Biopartners Dividends per Share Related Terms

Thank you for viewing the detailed overview of Arch Biopartners's Dividends per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Arch Biopartners (TSXV:ARCH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arch Biopartners Inc (TSXV:ARCH) » Definitions » Dividends per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

545 King Street West, Toronto, ON, CAN, M5V 1M1

Website

https://www.archbiopartners.com

Arch Biopartners Inc is a clinical stage company developing technologies with the potential to make medical or commercial impacts. The company is developing a drug platform Metablok to produce drug candidates to inhibit organ inflammation caused via the DPEP-1 pathway. It's under development portfolio is AB569, a potential new treatment for antibiotic resistant bacterial infections in the lungs or wounds; and, Borg peptide coatings that increase corrosion resistance and decrease bacterial biofilm on various medical grade metals and plastics.